SEARCH

SEARCH BY CITATION

References

  • Aerbajinai, W., Zhu, J., Gao, Z., Chin, K. & Rodgers, G.P. (2007) Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood, 110, 28642871.
  • Amrolia, P.J., Almeida, A., Davies, S.C. & Roberts, I.A.G. (2003) Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach. British Journal of Haematology, 120, 737743.
  • Atweh, G.F., Sutton, M., Nassif, I., Boosalis, V., Dover, G.J., Wallenstein, S., Wright, E., McMahon, L., Stamatoyannopoulos, G., Faller, D.V. & Perrine, S.P. (1999) Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood, 93, 17901797.
  • Bailey, K., Morris, J.S., Thomas, P. & Serjeant, G.R. (1992) Fetal haemoglobin and early manifestations of homozygous sickle cell disease. Archives of Disease in Childhood, 67, 517520.
  • Bank, A. (2006) Regulation of human fetal hemoglobin: new players, new complexities. Blood, 107, 435443.
  • Bernaudin, F., Verlhac, S., Coic, L., Lesprit, E., Brugieres, P. & Reinert, P. (2005) Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial doppler. Pediatric Radiology, 35, 242248.
  • Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.P., Yakouben, K., Thuret, I., Bordigoni, P., Fischer, A., Lutz, P., Stephan, J.L., Dhedin, N., Plouvier, E., Margueritte, G., Bories, D., Verlhac, S., Esperou, H., Coic, L., Vernant, J.P. & Gluckman, E. (2007) Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood, 110, 27492756.
  • Berthaut, I., Guignedoux, G., Kirsch-Noir, F., De Larouziere, V., Ravel, C., Bachir, D., Galacteros, F., Ancel, P.-Y., Kunstmann, J.-M., Levy, L., Jouannet, P., Girot, R. & Mandelbaum, M. (2008) Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica, 93, 988993.
  • Castro, O., Brambilla, D.J., Thorington, B., Reindorf, C.A., Scott, R.B., Gillette, P., Vera, J.C. & Levy, P.S. (1994) The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood, 84, 643649.
  • Chaine, B., Neonato, M.G., Girot, R. & Aractingi, S. (2001) Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Archives of Dermatology, 137, 467470.
  • Charache, S., Dover, G., Smith, K., Talbot, C.C., Moyer, M. & Boyer, S. (1983) Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proceedings of the National Academy of Sciences of the United States of America, 80, 48424846.
  • Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New England Journal of Medicine, 332, 13171322.
  • Choi, S.H., Byun, H.M., Kwan, J.M., Issa, J.P. & Yang, A.S. (2007) Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. British Journal of Haematology, 138, 616623.
  • Conley, C.L., Weatherall, D.J., Richardson, S.N., Shepard, M.K. & Charache, S. (1963) Hereditary persistance of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood, 21, 261.
  • Davies, S. & Olujohungbe, A. (2001) Hydroxyurea for sickle cell disease. Cochrane Database of Systematic Reviews, CD002202.
  • De Montalembert, M. (2007) Hydroxyurea: Benefits and Risks in Patients Affected with Sickle Cell Anemia. Hematology Education 2007 Book 1, Education Program, 12th EHA Annual Congress, http://www.ehaweb.org/education.
  • De Montalembert, M., Brousse, V., Elie, C., Bernaudin, F., Shi, J. & Landais, P., French Study Group on Sickle Cell Disease (2006) Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica, 91, 125128.
  • De Simone, J., Heller, P., Hall, L. & Zwiers, D. (1982) 5-azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proceedings of the National Academy of Sciences of the United States of America, 79, 44284431.
  • DeSimone, J., Koshy, M., Dorn, L., Lavelle, D., Bressler, L., Molokie, R. & Talischy, N. (2002) Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood, 99, 39053908.
  • Dover, G.J., Hunphries, R.K., Morre, J.G., Ley, T.J., Young, N.S., Charache, S. & Niehuis, A.W. (1986) Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood, 67, 735.
  • Dover, G.J., Brusilow, S. & Samid, D. (1992) Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. New England Journal of Medicine, 327, 569570.
  • Fathallah, H. & Atweh, G. (2006) DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical applications. Blood Reviews, 20, 227234.
  • Fathallah, H., Weinberg, R.S., Galperin, Y., Sutton, M. & Atweh, G. (2007) Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood, 110, 33913397.
  • Ferster, A., Vermylen, C., Cornu, G., Buyse, M., Corazza, F., Devalck, C., Fondu, P., Toppet, M. & Sariban, E. (1996) Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood, 88, 19601964.
  • Ferster, A., Tahriri, P., Vermylen, C., Sturbois, G., Corazza, F., Fondu, P., Devalck, C., Dresse, M.F., Feremans, W., Hunninck, K., Toppet, M., Philippet, P., Van Geet, C. & Sariban, E. (2001) Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood, 97, 36283632.
  • Fibach, E., Bianchi, N., Borgatti, M., Prus, E. & Gambari, R. (2003) Mithramycin induces fetal hemoglobin production in normal and thalassaemia human erythroid precursor cells. Blood, 15, 12761281.
  • Fitzhugh, C.D., Wigfall, D.R. & Ware, R.E. (2005) Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatric Blood Cancer, 45, 982985.
  • Franco, R.S., Yasin, Z., Palascak, M.B., Ciraolo, P., Joiner, C.H. & Rucknagel, D.L. (2006) The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood, 108, 10731076.
  • Frenette, P.S. & Atweh, G.F. (2007) Sickle cell disease: old discoveries, new concepts, and future promise. Journal of Clinical Investigation, 117, 850858.
  • Ghoshal, K., Datta, J., Majumdar, S., Bai, S., Kutay, H., Motiwala, T. & Jacob, S.T. (2005) 5-aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteosomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Molecular Cellular Biology, 25, 47274741.
  • Gulbis, B., Haberman, D., Dufour, D., Christophe, C., Vermylen, C., Kagambega, F., Corazza, F., Devalck, C., Dresse, M.F., Hunninck, K., Klein, A., Le, P.Q., Loop, M., Maes, P., Philippet, P., Sariban, E., Van Geet, C. & Ferster, A. (2005) Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events The Belgian experience. Blood, 105, 26852690.
  • Halsey, C. & Roberts, I.A.G. (2003) The role of hydroxyurea in sickle cell disease. British Journal of Haematology, 12, 177186.
  • Hankins, J.S., Ware, R.E., Rogers, Z.R., Wynn, L.W., Lane, P.A., Scott, J.P. & Wang, W.C. (2005) Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood, 106, 22692275.
  • Hankins, J., Helton, K.J., McCarville, M.B., Li, C.S., Wang, W.C. & Ware, R.E. (2008a) Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatric Blood Cancer, 50, 293297.
  • Hankins, J.S., Wynn, L.W., Brugnara, C., Hillery, C.A., Li, C.S. & Wang, W.C. (2008b) Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. British Journal of Haematology, 140, 8085.
  • Harrod, V.L., Howard, T., Abboud, M.R., Hankins, J., Lobo, C. & Ware, R.E. (2008) Chemical and functional analysis of generic hydroxyurea formulations. Pediatric Hematology Oncology, 25, 423429.
  • Heeney, M.M. & Ware, R.E. (2008) Hydroxyurea for children with sickle cell disease. Pediatric Clinics of North America, 55, 483501.
  • Hines, P., Dover, G.J. & Resar, L.M. (2008) Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatric Blood Cancer, 50, 357359.
  • Issa, J.P., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C.S., Cortes, J. & Kantarjian, H.M. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hemopoietic malignancies. Blood, 103, 16351640.
  • Jeng, M.R., Rieman, M.D., Naidu, P.E., Kaste, S.C., Jenkins, III, J.J., Serjeant, G. & Wang, W.C. (2003) Resolution of chronic hepatic sequestration in a patient with homozygous sickle cell disease receiving hydroxyurea. Journal of Pediatric Hematology Oncology, 25, 257260.
  • Kato, G.J., Gladwin, M.T. & Steinberg, M.H. (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews, 21, 3747.
  • Kaul, D.K., Liu, X.D., Chang, H.Y., Nagel, R.L. & Fabry, M.E. (2004) Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. Journal of Clinical Investigation, 114, 11361145.
  • Kinney, T.R., Helms, R.W., O’Branski, E.E., Ohene-Frempong, K., Wang, W., Daeschner, C., Vichinsky, E., Redding-Lallinger, R., Gee, B., Platt, O.S. & Ware, R.E. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood, 94, 15501554.
  • Koshy, M., Dorn, L., Bressler, L., Molokie, R., Lavelle, D., Talischy, N., Hoffman, R., Van Overveld, W. & DeSimone, J. (2000) 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood, 96, 23792384.
  • Kratovil, T., Bulas, D., Driscoll, C., Speller-Brown, B., McCarter, R. & Minniti, C.P. (2006) Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatric Blood Cancer, 47, 894900.
  • Kumkhaek, C., Taylor, VI, J.G., Zhu, J., Hoppe, C., Kato, G.J. & Rodgers, G.P. (2008) Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. British Journal of Haematology, 141, 254259.
  • Lampronti, I., Bianchi, N., Borgatti, M., Fibach, E., Prus, E. & Gambari, R. (2003) Accumulation of gamma-globin mRNA in human erythroid cells treated with angelicin. European Journal of Haematology, 71, 189195.
  • Lanzkron, S., Strause, J.J., Wilson, R., Beach, M.C., Haywood, C., Park, H., Witkop, C., Bass, E.B. & Segal, J.B. (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Annals of Internal Medicine, 148, 939955.
  • Lavelle, D., Chin, J., Vaitkus, K., Redkar, S., Phiasivongsa, P., Tang, C., Will, R., Hankewych, M., Roxas, B., Singh, M., Saunthararajah, Y. & Desimone, J. (2007) Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. American Journal of Hematology, 82, 981985.
  • Lee, M.T., Piomelli, S., Granger, S., Miller, S.T., Harkness, S., Brambilla, D.J. & Adams, R.J. STOP Study Investigators. (2006) Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood, 108, 847852.
  • Lefevre, N., Dufour, D., Gulbis, B., Le, P.Q., Heijmans, C. & Ferster, A. (2008) Use of hydroxyurea in prevention of stroke in children with sickle cell disease. Blood, 111, 963964.
  • Little, J.A., McGowan, V.R., Kato, G.J., Partovi, K.S., Feld, J.J., Maric, I., Martyr, S., Taylor, VI, J.G., Machado, R.F., Heller, T., Castro, O. & Gladwin, M.T. (2006) Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica, 91, 10761083.
  • Ma, Q., Wyszynski, D.F., Farrell, J.J., Kutlar, A., Farrer, L.A., Baldwin, C.T. & Steinberg, M.H. (2007) Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics Journal, 7, 386394.
  • Mabaera, R., Greene, M.R., Richardson, C.A., Conine, S.J., Kozul, C.D. & Lowrey, C.H. (2008) Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine’s ability to induce human fetal hemoglobin. Blood, 111, 411420.
  • McClish, D.K., Penberthy, L.T., Bovbjerg, V.E., Roberts, J.D., Aisiku, I.P., Levenson, J.L., Roseff, S.D. & Smith, W.R. (2005) Health related quality of life in sickle cell patients: the PISCES project. Health and Quality of Life Outcomes, 3, 50.
  • Miller, J.L. (2005) Signaled expression of fetal hemoglobin during development. Transfusion, 45, 12291232.
  • Modell, B., Darlison, M., Birgens, H., Cario, H., Faustino, P., Giordano, P.C., Gulbis, B., Hopmeier, P., Lena-Russo, D., Romao, L. & Theodorsson, E. (2007) Epidemiology of haemoglobin disorders in Europe: an overview. European Scandinavian Journal of Clinical and Laboratory Investigation, 67, 3969.
  • De Montalembert, M., Maunoury, C., Acar, P., Brousse, V., Sidi, D. & Lenoir, G. (2004) Myocardial ischaemia in children with sickle cell disease. Archives of Disease in Childhood, 89, 359362.
  • Moutouh-de Parseval, L.A., Verhelle, D., Glezer, E., Jensen-Pergakes, K., Ferguson, G.D., Corral, L.G., Morris, C.L., Muller, G., Brady, H. & Chan, K. (2008) Pomalidomide and lenalidomide regulate erythropoiesis and fetal haemoglobin production in human CD34+ cells. Journal of Clinical Investiagtion, 118, 248258.
  • NHS Sickle Cell and Thalassaemia Screening Programme (2007) Sickle Cell disease in Childhood – Standards and Guidelines for Clinical Care. Detailed Guidance. http://www.nhs.uk/sickleandthal.org.uk/Documents/DETAILED_CLIN_Oct19.pdf .
  • O’Branski, E.E., Ware, R.E., Prose, N.S. & Kinney, T.R. (2001) Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. Journal of the American Academy of Dermatology, 44, 859861.
  • Perrine, R.P., Pembrey, M.E., John, P., Perrine, S. & Shroup, F. (1978) Natural history of sickle cell anaemia in Saudi Arabs. A study of 270 subjects. Annals of Internal Medicine, 88, 16.
  • Platt, O.S. (2008) Hydroxyurea for the treatment of sickle cell anemia. New England Journal of Medicine, 358, 13621369.
  • Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 16391644.
  • Poillon, W.N., Kim, B.C., Rodgers, G.P., Noguchi, C.T. & Schechter, A.N. (1993) Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiological ligand saturations. Proceedings of the National Academy of Sciences of the United States of America, 90, 50395043.
  • Powars, D.R., Chan, L.S., Hiti, A., Ramicone, E. & Johnson, C. (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore), 84, 363376.
  • Quinn, C.T., Rogers, Z.R. & Buchanan, G.R. (2004) Survival of children with sickle cell disease. Blood, 103, 40234027.
  • Resar, L., Segal, J. B., Fitzpatric, L.K., Friedmann, A., Brusilow, S.W. & Dover, G.J. (2002) Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. Journal of Pediatric Hematology Oncology, 24, 737741.
  • Roach, E.S., Golomb, M.R., Adams, R., Biller, J., Daniels, S., Deveber, G., Ferriero, D., Jones, B.V., Kirkham, F.J., Scott, R.M. & Smith, E.R. American Heart Association Stroke Council; Council on Cardiovascular Disease in the Young. (2008) Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke, 39, 26442691.
  • Roberts, I. & De Montalembert, M. (2007) Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe. Haematologica, 92, 865871.
  • Rotter, M., Aprelev, A., Adachi, K. & Ferrone, F.A. (2005) Molecular crowding limits the role of fetal hemoglobin in therapy for sickle cell disease. Journal of Molecular Biology, 347, 10151023.
  • Sadelain, M. (2006) Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Current Opinions in Hematology, 13, 142148.
  • Saunthararajah, Y., Hillery, C.A., Lavelle, D., Molokie, R., Dorn, L., Bressler, L., Gavazova, S., Chen, Y.H., Hoffman, R. & DeSimone, J. (2003) Effects of 5-aza-2’-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood, 102, 38653870.
  • Saunthararajah, Y., Molokie, R., Saraf, S., Sidhwani, S., Gowhari, M., Vara, S., Lavelle, D. & DeSimone, J. (2008) Clinical effectiveness of decitabine in severe sickle cell disease. British Journal of Haematology, 141, 126129.
  • Singh, S.A., Koumbourlis, A.C. & Aygun, B. (2008) Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. Pediatric Blood and Cancer, 50, 12581260.
  • Spencer, F., Chi, L. & Zhu, M.X. (2000) Hydroxyurea inhibition of cellular and developmental activities in the decidualized and pregnant uteri of rats. Journal of Applied Toxicology, 20, 407412.
  • Sumoza, A., De Bisotti, R., Sumoza, D. & Fairbanks, V. (2002) Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). American Journal of Hematology, 71, 161165.
  • Telfer, P., Coen, P., Chakravorty, S., Wilkey, O., Evans, J., Newell, H., Smalling, B., Amos, R., Stephens, A., Rogers, D. & Kirkham, F. (2007) Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica, 92, 905912.
  • Thauvin-Robinet, C., Maingueneau, C., Robert, E., Elefant, E., Guy, H., Caillot, D., Casasnovas, R.O., Douvier, S. & Nivelon-Chevallier, A. (2001) Exposure to hydroxyurea during pregnancy: a case series. Leukemia, 15, 13091311.
  • Vichinsky, E.P. & Lubin, B.H. (1994) A cautionary note regarding hydroxyurea in sickle cell disease. Blood, 83, 11241128.
  • Wang, W.C., Wynn, L.W., Rogers, Z.R., Scott, J.P., Lane, P.A. & Ware, R.E. (2001) A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Journal of Pediatrics, 139, 790796.
  • Wang, W.C., Helms, R.W., Lynn, H.S., Redding-Lallinger, R., Gee, B.E., Ohene-Frempong, K., Smith-Whitley, K., Waclawiw, M.A., Vichinsky, E.P., Styles, L.A., Ware, R.E. & Kinney, T.R. (2002) Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. Journal of Pediatrics, 140, 225229.
  • Ware, R.E., Zimmerman, S.A. & Schultz, W.H. (1999) Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood, 94, 30223026.
  • Ware, R.E., Eggleston, B., Redding-Lallinger, R., Wang, W.C., Smith-Whitley, K., Daeschner, C., Gee, B., Styles, L.A., Helms, R.W., Kinney, T.R. & Ohene-Frempong, K. (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood, 99, 1014.
  • Watson, J. (1948) The significance of the paucity of sickle cells in newborn Negro infants. American Journal of the Medical Sciences, 215, 419.
  • Weatherall, D.J. & Clegg, J.B. (2001) Inherited haemoglobin disorders: an increasing global health problem. Bulletin of the World Health Organisation, 79, 704712.
  • Weinberg, R.S., Ji, X., Sutton, M., Errine, S., Galperin, Y., Li, Q., Liebhaber, S.A., Stamatoyannopoulos, G. & Atweh, G.F. (2005) Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood, 105, 18071809.
  • Zimmerman, S.A., Schultz, W.H., Davis, J.S., Pickens, C.V., Mortier, N.A., Howard, T.A. & Ware, R.E. (2004) Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood, 103, 20392045.
  • Zimmerman, S.A., Schultz, W.H., Burgett, S., Mortier, N.A. & Ware, R.E. (2007) Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood, 110, 10431047.